Doctors could sidestep “onerous” prescribing obligations for the etanercept biosimilar Brenzys under new recommendations by the PBAC, which has flexed its differential prescribing powers for the first time. In May, the government outlined two new policies to drive the uptake of biosimilars to curb spending on biologic drugs like etanercept (Enbrel), which at $167 million ...
Concern over unprecedented intervention into biologics market
By Tessa Hoffman
19 Oct 2017